Gongwin Biopharm Holdings Co., Ltd. (6617.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$115.00 (-0.43%) as of
Key statistics
- EPS (TTM)
- -1.32
- Dividend yield
- 0.00%
- 52-week range
- 58.30 – 149.00
- Beta
- 0.31
- Revenue (TTM)
- 42.22M
- Profit margin
- 0.00%
- Volume
- 102.93k
About Gongwin Biopharm Holdings Co., Ltd.
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company also develops animal medicines; engaged in the pet medical business; and wholesale and retail of the medical equipment. Gongwin Biopharm Holdings Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.
Related stocks
- TYC BROTHER INDUSTRIAL (1522.TW)
- NIDEC CHAUN-CHOUNG TECHNOLOGY C (6230.TW)
- MAGNATE TECHNOLOGY CO LTD (4541.TWO)
- YUAN HIGH-TECH DEVELOPMENT CO (5474.TWO)
- STANDARD FOODS CORPORATION (1227.TW)
- U-BEST INNOVATIVE TECHNOLOGY CO (4714.TWO)
- PROFESSIONAL COMPUTER TECHNOLOG (6270.TWO)
- SPECTRUM ELECTRICS CORPORATION (5381.TWO)